Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Adam Kluger Public Relations (www.adamklugerpr.com) announced today that Dr. Dennis Lin, MD (www.drdennismd.com) has retained the New York based boutique PR firm to provide media support and to promote his psychiatric practice which specializes in sexology, sexual relationships, interpersonal difficulties and couples therapy.

26 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

15 Oct 2009

National Institutes of Health grants $12 million to WCDRC for obesity research

The Miriam Hospital's Weight Control and Diabetes Research Center (WCDRC) recently received six research grants from the National Institutes of Health - totaling more than $12 million in funding - that will support the work of researchers focused on the prevention and treatment of obesity.

15 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Use of minimally invasive procedures for radical prostatectomy has advantages as well as complications

New research indicates that the use of minimally invasive procedures (including the use of robotic assistance) for radical prostatectomy, which have increased significantly in recent years, may shorten hospital stays and decrease respiratory and surgical complications, but may also result in an increased rate of certain complications, including incontinence and erectile dysfunction, according to a study in the October 14 issue of JAMA, a theme issue on surgical care.

14 Oct 2009

Roche scientist honored with 2009 Meienhofer Award for excellence in peptide chemistry

Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored last week as the 2009 recipient of the Meienhofer Award for excellence in peptide chemistry at the international peptide symposium, RCCPS (http://www.rochecolorado.com/PeptideSymp09/).

8 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.

30 Sep 2009

Sexual satisfaction and general well-being linked: Study

Pre- and post-menopausal women who self-rated themselves as being sexually satisfied had a higher overall psychological well-being score and scores for "positive well-being" and "vitality," compared with sexually dissatisfied women in a study of 295 women sexually active more than twice a month. The study, published today in The Journal of Sexual Medicine, also uncovered a positive association between age and well-being, but a negative association for general health.

30 Sep 2009

Urodynamix closes $1.5 million non-brokered private placement for common shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it has closed a $1.5 million non-brokered private placement for 30,000,000 common shares previously reported on September 11, 2009.

29 Sep 2009

$Diabetic patients face increased risk of bone fractures$

Diabetic patients face increased risk of bone fractures

Current research suggests that the inflammatory molecule TNF-α may contribute to delayed bone fracture healing in diabetics. The related report by Alblowi et al, "High Levels of TNF-α Contribute to Accelerated Loss of Cartilage in Diabetic Fracture Healing" appears in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Androgen deficiency linked to diabetes and cardiovascular diseases

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.

25 Sep 2009

Results of American Medical Systems Holdings' exchange offer announced

American Medical Systems Holdings, Inc. (NASDAQ: AMMD) (the “Company”), today announced the results of its exchange offer (the “Exchange Offer”) in which the Company offered $1,000 principal amount of its newly issued 4.00% Convertible Senior Subordinated Notes due 2041 (the “2041 Notes”) in exchange for each $1,000 principal amount of its outstanding 3.25% Convertible Senior Subordinated Notes due 2036 (the “2036 Notes”), for up to $250 million, and no less than $100 million, aggregate principal amount of 2036 Notes.

18 Sep 2009

Study reveals that older widowers are likely to be diagnosed with a STD

Widowers take care: Older men who have recently lost their wives are more likely than still-married peers to be diagnosed with a sexually transmitted disease (STD), according to a new study.

18 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.

8 Sep 2009

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

Oxygen Biotherapeutics announces its expanded product development plan

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

National Institutes of Health grants $12 million to WCDRC for obesity research

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Use of minimally invasive procedures for radical prostatectomy has advantages as well as complications

Roche scientist honored with 2009 Meienhofer Award for excellence in peptide chemistry

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Fifth SEEM anniversary meeting to be held in Belgrade

Urodynamix: Cross of 1,480,000 common shares effected through Canaccord Capital

Sexual satisfaction and general well-being linked: Study

Urodynamix closes $1.5 million non-brokered private placement for common shares

Diabetic patients face increased risk of bone fractures

Androgen deficiency linked to diabetes and cardiovascular diseases

Results of American Medical Systems Holdings' exchange offer announced

Study reveals that older widowers are likely to be diagnosed with a STD

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in